HC Wainwright has adjusted its Q1 2026 earnings forecast for Gain Therapeutics, now expecting a smaller loss per share of ($0.13) and maintaining a "Buy" rating with an $8.00 price target, following better-than-expected earnings.

NodeGuardian

2026-04-19 05:52:03

Abstract generation in progress

HC Wainwright has revised its Q1 2026 earnings estimates for Gain Therapeutics (NASDAQ:GANX), now projecting a smaller loss per share of ($0.13), an improvement from their previous forecast of ($0.15). The firm maintains a “Buy” rating and an $8.00 price target for the stock. This update follows Gain Therapeutics’ recent earnings report where they surpassed consensus estimates by reporting ($0.11) EPS against a projected ($0.14).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
236.69K Popularity
#
Gate13thAnniversaryLive
877.86K Popularity
#
AltcoinsRallyStrong
7.36M Popularity
#
AnthropicvsOpenAIHeatsUp
1.08M Popularity
#
KalshiFacesNevadaRegulatoryClash
477.87K Popularity

Sitemap

HC Wainwright Has Positive Estimate for GANX Q1 Earnings

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin